Very nice QTRLY, progress on ROW, re submitting of NNZ-2591 for multiple neurodevelopmental disorders and • $36.8 million cash at 31 December 2021 – well funded to execute NNZ-2591 trials and
foundational work for Phase 3 across all indications.
What's NOT to Like? Yet we get some crazy constant selling of a few shares, pushing down the SP as she starts to run.
it is very frustrating to watch.
Ann: Q4 2021 quarterly activity and cash flow report, page-7
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.30 |
Change
-0.200(1.03%) |
Mkt cap ! $2.468B | |||
| Open | High | Low | Value | Volume |
| $19.50 | $19.59 | $19.19 | $3.165M | 163.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 144 | $19.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.31 | 24 | 2 |
View Market Depth
| Last trade - 13.57pm 10/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |